Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Majalah Patologi Indonesia
Chrestela, Jessy
Unknown Affiliation
Health Professions Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Immunohistochemistry Expression Gata3 Based on Subtypes of Ovarian Carcinoma at Haji Adam Malik General Hospital Medan 2019-2021 Alamanda, Intan Nefia; Betty, Betty; Delyuzar, Delyuzar; Laksmi, Lidya Imelda; Chrestela, Jessy; Soekimin, Soekimin
Majalah Patologi Indonesia Vol. 33 No. 3 (2024): MPI
Publisher : Perhimpunan Dokter Spesialis Patologi Anatomik Indonesia (PDSPA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55816/mpi.v33i2.604

Abstract

Background Ovarian carcinoma is a cancer with high mortality in women and although comprehensive management with surgery and chemotherapy at an advanced stage, the resistance rate is still low. GATA3 contributes to the progression of malignancy and its expression is one of the predictors in some malignancies, but the results are mixed in ovarian carcinoma. High GATA3 expression is associated with the aggressiveness of tumor growth and poor prognosis of ovarian carcinoma.   Methods This research is an cross-sectional descriptive-analytical study with 33 histological specimens diagnosed with ovarian carcinoma from medical records/archives at H. Adam Malik Hospital Medan. Each sample specimen was stain with GATA3, and several various histopathological subtypes of ovarian carcinoma.   Results From a total of 33 samples, 14 samples were serous carcinoma, 6 samples were mucinous carcinoma, 7 samples were endometrioid carcinoma, and 6 samples were clear cell carcinoma. GATA3 was expressed in 42.5% of serous carcinoma. Positive expression of GATA3 is mostly found in advanced ovarian carcinoma, older age, and histopathological type of serous carcinoma.    Conclusion Immunohistochemistry GATA3 expression was expressed in 42.4% of serous carcinoma, 21.2% in endometrioid carcinoma, 18.2% in clear cell carcinoma, and 18.2% in mucinous carcinoma.   Keywords: ovarian carcinoma, GATA3, immunohistochemistry
Correlation Ki67 Expression With peritumoral budding Tumor Index In the Case of Squamous Cell Carcinoma Cervix NOS And Adenocarcinoma Cervix NOS Wardini, Indah Astri; Alferraly, T. Ibnu; Chrestela, Jessy; Betty, Betty; Intan, T. Kemala; Lubis, H. M. Nadjib Dahlan
Majalah Patologi Indonesia Vol. 33 No. 3 (2024): MPI
Publisher : Perhimpunan Dokter Spesialis Patologi Anatomik Indonesia (PDSPA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55816/mpi.v33i3.611

Abstract

Background Cervical cancer is a neoplasm in the cervix due to abnormal cells that damage the surrounding tissue. Cervical cancer from squamous cells is called squamous cell carcinoma cervix NOS and that from glands is called adenocarcinoma cervix NOS. The prognostic of both can be assessed by tumor budding and Ki67 immunohistochemistry, tumor budding is a tumor bud which is ≤ 5 cells in a cluster that grows in front of the parent tumor and immunohistochemistry Ki67 is a labile nonhistone nuclear protein which is expressed in the G1, S, G2 and M phases of the cycle cell.   Method This research is an analytical type of research that aims to find out the relationship between Ki67 expression and the peritumoral budding tumor index compared to cases of squamous cell carcinoma cervix NOS and adenocarcinoma cervix NOS with 36 paraffin block samples diagnosed with squamous cell carcinoma NOS and adenocarcinoma NOS at HAM Hospital. Medan. Assessment method of Ki67 expression where low expression (<20%) and high expression (≥20%). Assessment of peritumoral budding tumors in both cases was said to be low buds if < 5 buds and high buds if ≥ 5 buds. Results This study provides a significant appearance (p-value 0.0001) which means that peritumoral budding tumors with HE staining can be accepted as a measuring tool for assessing cervical cancer in addition to assessment using immunohistochemistry Ki67 which is generally used in the prognostic assessment of cervical cancer. Conclusion Assessment in this case can consider peritumoral budding tumor assessment to determine prognostic in cases of squamous cell carcinoma NOS and cervical adenocarcinoma NOS, if Ki67 immunohistochemistry is not available.
Co-Authors Alamanda, Intan Nefia Alferraly, T. Ibnu betty betty Delyuzar, Delyuzar Intan, T. Kemala Laksmi, Lidya Imelda Lubis, H. M. Nadjib Dahlan Soekimin Soekimin, Soekimin Wardini, Indah Astri